Dr. Alan McNeill has 30 years of experience in the pharmaceutical industry, both within large pharma and CROs, in 14C radiosynthesis. From this, he has developed an in depth understanding of the requirements for a successful and cost-effective labelling strategy to deliver 14C labelled APIs to support pre-clinical and clinical studies. 

Alan holds a PhD in Organic Chemistry from the University of Manchester.